top of page
  • Recruiting

NCT03689595: PROMISE - Predicting Progression of Developing MM in a High-Risk Screened Population

Updated: Sep 24, 2022


NCT03689595: PROMISE - Predicting Progression of Developing MM in a High-Risk Screened Population


The PROMISE Study aims to establish a prospective cohort of individuals with precursor conditions to multiple myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma.


Collaborator Identifier: NCT03689595

Official Title: Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)

First Posted : September 28, 2018

Click here for details on


Learn more:

The PCROWD Study invites people with precursor conditions to Share samples a few times each year

IMPACT Study: The Immune Profiling with Antibody-based COVID-19 Testing (IMPACT) study


Learn more:

The Promise Study: How a Blood Test Can Detect, Intercept, and Potentially Eliminate Cancer

Dana-Farber Cancer Institute

Dana Farber Cancer Institute

Jan 31, 2022


Learn more:

Dr. Irene Ghobrial | CPOP | Dana-Farber Cancer Institute

Dana-Farber’s Center for the Prevention of Progression (CPOP)

Dana-Farber Cancer Institute

Learn more:

MGUS/Smoldering Myeloma PCrowd Study by Dr. Irene Ghobrial

Myeloma Crowd by HealthTree


- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston


152 High Prevalence of Monoclonal Gammopathy in a Population at Risk: The First Results of the Promise Study

Program: Oral and Poster Abstracts

Type: Oral

Session: 652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Monoclonal Gammopathies of Determined Significance: What We Have and What We Want

Hematology Disease Topics & Pathways:

Adults, Plasma Cell Disorders, Clinically Relevant, Diseases, Disparities, Lymphoid Malignancies, Technology and Procedures, Study Population, Diversity, Equity, and Inclusion (DEI), Clinical Practice (e.g. Guidelines, Health Outcomes and Services, and Survivorship, Value; etc.), Serologic Tests

Saturday, December 11, 2021: 12:15 PM


Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study

Lancet Haematol; 2022

Click here for details


Posts Archive
bottom of page